GO:0180062 protein O-linked glycosylation via galactose: Glycoprotein Biosynthesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0180062 describes a glycoprotein biosynthetic process that begins with the covalent attachment of galactose via a beta-glycosidic bond to hydroxyproline, hydroxylysine, serine, or threonine residues in proteins.
• Hydroxylysine-linked galactosylation occurs in the endoplasmic reticulum and is predominantly found in collagen, while hydroxyproline-linked galactosylation occurs in the Golgi and is found only in plant proteins.
• This process is critical for protein folding, stability, and function, and its dysregulation is linked to diseases such as IgA nephropathy and collagen disorders [2,3].
• Key enzymes include galactosyltransferases such as COLGALT1 and COLGALT2, which catalyze the transfer of galactose to hydroxylysine residues in collagens.
• In biopharmaceutical production, galactosylation of monoclonal antibodies in Chinese hamster ovary (CHO) cells is a critical quality attribute that can be modulated by culture conditions [4,5].
• Emerging research shows that host galactosylation influences pathogen infection, including HIV-1 tropism and gut microbiota regulation [6,7].
Description
Protein O-linked glycosylation via galactose (GO:0180062) is a post-translational modification that initiates with the covalent attachment of galactose to specific hydroxylated amino acids in proteins. This process is essential for the biosynthesis of glycoproteins and plays a fundamental role in protein structure, stability, and function. The modification occurs on hydroxyproline, hydroxylysine, serine, or threonine residues, with hydroxylysine modification predominantly found in collagens within the endoplasmic reticulum, and hydroxyproline modification occurring in the Golgi of plant proteins. Understanding this pathway is crucial for researchers in glycobiology, biomedicine, and biopharmaceutical development, as it impacts a wide range of biological processes from extracellular matrix assembly to immune regulation [2,3]. Dysregulation of galactosylation has been implicated in human diseases, including IgA nephropathy and collagen-related disorders, making it a significant area of study [2,3]. Moreover, the galactosylation of therapeutic monoclonal antibodies produced in CHO cells is a critical quality attribute that affects antibody effector functions and pharmacokinetics [4,5]. Recent studies have also highlighted the role of host galactosylation in pathogen interactions, such as HIV-1 infection and gut microbiota regulation, underscoring its broad biological significance [6,7].
protein O-linked glycosylation via galactose At A Glance
| GO ID | GO:0180062 |
|---|---|
| GO term | protein O-linked glycosylation via galactose |
| Ontology | biological_process |
| Synonym | protein O-linked galactosylation |
| Major function | Covalent attachment of galactose to hydroxyproline, hydroxylysine, serine, or threonine residues in proteins, initiating O-linked glycan formation |
| Subcellular location | Endoplasmic reticulum (for hydroxylysine modification) and Golgi (for hydroxyproline modification) |
| Predominant protein context | Collagen (hydroxylysine modification) and plant proteins (hydroxyproline modification) |
| Related enzymes | Galactosyltransferases such as COLGALT1 and COLGALT2 |
What Is GO:0180062?
GO:0180062, protein O-linked glycosylation via galactose, is defined as a glycoprotein biosynthetic process that starts with the covalent linkage of galactose via a beta-glycosidic bond to the oxygen atom of the hydroxyl group of a hydroxyproline, hydroxylysine, serine, or threonine in a protein. This initial step can be further elongated with the sequential addition of sugar units, resulting in the formation of a protein O-linked glycan. Hydroxylysine modification occurs in the endoplasmic reticulum and is predominantly found in collagen, while hydroxyproline modification occurs in the Golgi and is found only in plant proteins.
Why Is protein O-linked glycosylation via galactose Important in Cell Biology?
Protein O-linked glycosylation via galactose is a fundamental post-translational modification that influences protein folding, stability, and interactions, and it is essential for the proper function of collagens and other glycoproteins. Its dysregulation is associated with human diseases, including IgA nephropathy, where aberrant galactosylation of IgA1 plays a key role in pathogenesis [2,3]. In biotechnology, the galactosylation profile of therapeutic monoclonal antibodies is a critical quality attribute that affects their efficacy and safety, and it can be modulated by culture conditions in CHO cells [4,5]. Furthermore, host galactosylation has been shown to influence pathogen infection and gut microbiota, highlighting its broader biological importance [6,7].
• Critical for collagen biosynthesis and extracellular matrix stability, with defects linked to connective tissue disorders.
• Aberrant galactosylation of IgA1 is a hallmark of IgA nephropathy, a leading cause of kidney failure [2,3].
• Modulates antibody effector functions and pharmacokinetics, impacting therapeutic monoclonal antibody development [4,5].
• Influences host-pathogen interactions, including HIV-1 tropism and gut microbiota regulation [6,7].
• Plays a role in plant cell wall structure and function through hydroxyproline-linked galactosylation.
• Serves as a quality attribute in biopharmaceutical production, where galactosylation levels are optimized for product consistency [4,5].
• Provides potential targets for therapeutic intervention in diseases characterized by abnormal glycosylation [2,3].
• Enables research into glycoprotein engineering and glycan-based diagnostics [4,5].
What Happens During protein O-linked glycosylation via galactose?
Initiation: Covalent Attachment of Galactose
In simple terms: The process starts when a sugar called galactose gets attached to specific amino acids in a protein.
The first step in protein O-linked glycosylation via galactose is the covalent linkage of galactose via a beta-glycosidic bond to the oxygen atom of the hydroxyl group of a hydroxyproline, hydroxylysine, serine, or threonine residue in a protein. This reaction is catalyzed by specific galactosyltransferases, such as COLGALT1 and COLGALT2, which transfer galactose from UDP-galactose to the hydroxyl group of hydroxylysine in collagens. This modification occurs in the endoplasmic reticulum for hydroxylysine residues and is predominantly found in collagen.
Elongation: Sequential Addition of Sugar Units
In simple terms: After galactose is attached, more sugars can be added one by one to form a longer glycan chain.
Following the initial galactose attachment, the O-linked glycan can be further elongated with the sequential addition of sugar units, resulting in the formation of a mature protein O-linked glycan. This elongation process involves various glycosyltransferases that add monosaccharides such as glucose, galactose, or others, depending on the protein and cell type. The specific structure of the glycan influences protein function and interactions.
Subcellular Compartmentalization
In simple terms: Different steps happen in different parts of the cell, like the endoplasmic reticulum and the Golgi.
Hydroxylysine modification occurs in the endoplasmic reticulum and is predominantly found in collagen, whereas hydroxyproline modification occurs in the Golgi and is found only in plant proteins. This compartmentalization ensures that glycosylation is properly regulated and that the correct glycans are added to the appropriate proteins.
Role in Collagen Biosynthesis
In simple terms: This process is especially important for making collagen, a key structural protein in the body.
In collagen, galactosylation of hydroxylysine residues is a critical step in collagen biosynthesis, contributing to the stability and cross-linking of collagen fibrils. Defects in this process can lead to connective tissue disorders.
Plant-Specific Hydroxyproline Galactosylation
In simple terms: Plants have a similar process that modifies proteins in their Golgi apparatus.
In plants, hydroxyproline-linked galactosylation occurs in the Golgi and is found only in plant proteins, where it plays roles in cell wall structure and signaling. This plant-specific modification highlights the evolutionary conservation and diversification of O-glycosylation pathways.
Key Genes Involved in GO:0180062 protein O-linked glycosylation via galactose
The following genes encode enzymes and proteins directly involved in or regulating protein O-linked glycosylation via galactose, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| COLGALT1 | Galactosyltransferase that transfers galactose to hydroxylysine residues in collagens | Mutations linked to collagen disorders; target for studying collagen biosynthesis |
| COLGALT2 | Galactosyltransferase involved in O-linked glycosylation of collagens | Potential role in extracellular matrix assembly and disease |
| GLT25D1 | Galactosyltransferase that modifies hydroxylysine in collagen | Studied for its role in collagen glycosylation and secretion |
| GLT25D2 | Galactosyltransferase with similar function to GLT25D1 | Implicated in collagen-related pathologies |
| PLOD1 | Lysyl hydroxylase that generates hydroxylysine for galactosylation | Defects cause Ehlers-Danlos syndrome type VI |
| PLOD2 | Lysyl hydroxylase involved in collagen cross-linking | Associated with fibrosis and cancer progression |
| PLOD3 | Lysyl hydroxylase that hydroxylates lysine residues in collagen | Mutations linked to connective tissue disorders |
| B4GALT1 | Beta-1,4-galactosyltransferase that can elongate O-glycans | Involved in glycan elongation and antibody production |
| B4GALT2 | Beta-1,4-galactosyltransferase family member | Potential role in glycosylation of therapeutic proteins |
| B3GALT6 | Beta-1,3-galactosyltransferase involved in glycosaminoglycan synthesis | Mutations cause connective tissue disorders |
| GALNT1 | Polypeptide N-acetylgalactosaminyltransferase that initiates O-glycosylation | Not directly in galactose O-linked pathway but related |
| GALNT2 | Initiates O-glycosylation on serine/threonine residues | Cross-talk with galactose O-linked pathway |
| UDP-Galactose transporter (SLC35A2) | Transports UDP-galactose into the Golgi for glycosylation | Defects cause congenital disorders of glycosylation |
| SLC35A3 | Transports UDP-GlcNAc, indirectly affecting galactosylation | Related to glycosylation disorders |
| FUT8 | Fucosyltransferase that competes with galactosylation in antibody production | Modulates antibody glycan profiles |
| MGAT1 | N-acetylglucosaminyltransferase involved in N-glycan processing | Indirectly affects O-linked galactosylation |
| B3GNT2 | Beta-1,3-N-acetylglucosaminyltransferase that can elongate glycans | Potential role in glycan branching |
| ST6GAL1 | Sialyltransferase that adds sialic acid to galactose residues | Modifies terminal galactose in glycans |
How Is protein O-linked glycosylation via galactose Regulated?
The regulation of protein O-linked glycosylation via galactose involves multiple layers of control, including the availability of UDP-galactose, the expression and activity of specific galactosyltransferases, and the subcellular localization of these enzymes. In biopharmaceutical production, culture conditions such as carbon dioxide partial pressure can influence galactosylation levels of monoclonal antibodies in CHO cells. Additionally, inflammatory cytokines such as APRIL and IL-6 can induce aberrant IgA glycosylation in IgA nephropathy, highlighting the role of immune signaling in regulating this process. Host galactosylation can also be modulated by the gut microbiota, as shown by ILC3s regulating intestinal galactosylation to limit pathogen infection.
protein O-linked glycosylation via galactose and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| COLGALT1 | Collagen disorders, connective tissue defects | Knockout in fibroblasts or chondrocytes to study collagen secretion |
| COLGALT2 | Extracellular matrix abnormalities | Knock-in of patient mutations in cell lines |
| PLOD1 | Ehlers-Danlos syndrome type VI | Point mutation knock-in in HEK293 cells |
| B4GALT1 | Antibody glycosylation defects | Overexpression in CHO cells for glycoengineering |
| SLC35A2 | Congenital disorders of glycosylation | Knockout in HeLa cells to study UDP-galactose transport |
IgA Nephropathy
IgA nephropathy is characterized by aberrant galactosylation of IgA1, leading to the formation of immune complexes that deposit in the glomeruli and cause kidney damage. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways, contributing to disease pathogenesis. This highlights the critical role of O-linked galactosylation in immune regulation and kidney disease [2,3].
Collagen-Related Disorders
Defects in the galactosylation of hydroxylysine residues in collagen can lead to connective tissue disorders, as this modification is essential for collagen stability and cross-linking. Mutations in genes encoding galactosyltransferases such as COLGALT1 have been associated with collagenopathies.
Infectious Diseases
Host cell glycosylation, including galactosylation, can influence pathogen infection. For example, host cell glycosylation selects for infection with CCR5- versus CXCR4-tropic HIV-1, affecting viral tropism. Additionally, intestinal galactosylation regulated by ILC3s limits pathogen infection in mice, demonstrating a role in host defense.
Biopharmaceutical Quality
In the production of therapeutic monoclonal antibodies, galactosylation is a critical quality attribute that affects antibody effector functions and pharmacokinetics. Modulation of antibody glycosylation in CHO cells through experimental and computational analyses provides mechanistic insights for process optimization [4,5].
From protein O-linked glycosylation via galactose-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does COLGALT1 loss affect collagen galactosylation? | CRISPR knockout in human fibroblasts |
| What is the effect of a specific point mutation in PLOD1 on hydroxylysine formation? | Point mutation knock-in in HEK293 cells |
| Can overexpression of B4GALT1 enhance antibody galactosylation? | Overexpression in CHO cells |
| How does tagged COLGALT2 localize within the ER/Golgi? | Tagged knock-in with fluorescent protein in HeLa cells |
| Does SLC35A2 deficiency alter O-linked galactosylation? | Knockout in induced pluripotent stem cells |
| What is the impact of gut microbiota on intestinal galactosylation? | Germ-free mouse models with ILC3 depletion |
How to Study the protein O-linked glycosylation via galactose Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry | Glycan composition and site-specific glycosylation | Characterizing IgA1 and collagen glycans |
| Lectins (Jacalin, HPA) | Galactose-deficient IgA1 | Diagnosis and monitoring of IgA nephropathy |
| CRISPR knockout screens | Genes affecting galactosylation | Identifying novel regulators in CHO cells |
| Computational modeling | Predictive glycosylation profiles | Bioprocess optimization |
| Flow cytometry | Cell surface glycan expression | Assessing intestinal galactosylation |
| Immunohistochemistry | Tissue distribution of galactosylated proteins | Studying collagen in connective tissues |
| Western blot | Protein expression and modification | Validating knockout or overexpression |
| qPCR | Gene expression levels | Measuring glycosyltransferase transcripts |
Glycomics and Mass Spectrometry
Mass spectrometry-based glycomics is essential for characterizing O-linked glycans, including galactose modifications, on proteins such as IgA1 and collagens [2,3]. This method allows precise identification of glycan structures and site occupancy.
Lectins and Antibodies
Lectins such as Jacalin and Helix pomatia agglutinin (HPA) can detect galactose-deficient IgA1, a hallmark of IgA nephropathy. These tools are valuable for diagnostic and research applications.
CRISPR Screening
Genome-wide CRISPR screens can identify genes regulating galactosylation, such as glycosyltransferases and transporters, by selecting for altered glycan profiles. This approach enables discovery of novel regulators.
Computational Modeling
Experimental and computational analyses provide mechanistic insights into antibody glycosylation in CHO cells, predicting how culture conditions affect galactosylation. Such models guide bioprocess optimization.
How CRISPR Can Be Used to Study GO:0180062 protein O-linked glycosylation via galactose
Knockout
CRISPR knockout of genes such as COLGALT1 or COLGALT2 can abolish galactosylation of specific proteins, enabling studies of their function in collagen biosynthesis and extracellular matrix assembly. Knockout models are valuable for dissecting the consequences of loss of galactosylation in disease contexts.
Point Mutation
Introducing point mutations in genes like PLOD1 or COLGALT1 via CRISPR can mimic patient-specific mutations, allowing researchers to study the effects on enzyme activity and protein glycosylation. This approach helps establish causality between genetic variants and disease phenotypes.
Knock-in
Knock-in of tagged versions of glycosyltransferases, such as fluorescently labeled COLGALT2, enables live-cell imaging and localization studies within the endoplasmic reticulum and Golgi. This provides insights into the spatiotemporal dynamics of O-linked galactosylation.
Overexpression
CRISPR activation or cDNA overexpression of B4GALT1 in CHO cells can enhance galactosylation of therapeutic antibodies, improving their effector functions. Overexpression models are useful for bioprocess engineering and glycan remodeling.
How EDITGENE Supports protein O-linked glycosylation via galactose Research
Researchers studying protein O-linked glycosylation via galactose-related genes often need to determine whether a candidate gene is causally involved in the pathway, how mutations affect glycan structures, and whether modulating its activity can alter disease phenotypes or biopharmaceutical quality attributes. EDITGENE provides comprehensive CRISPR-based services to address these questions with precision and scale.
Contact EDITGENE today to design your custom CRISPR model for protein O-linked glycosylation via galactose research.
Frequently Asked Questions About protein O-linked glycosylation via galactose
What is protein O-linked glycosylation via galactose?
It is a glycoprotein biosynthetic process that starts with the covalent attachment of galactose via a beta-glycosidic bond to hydroxyproline, hydroxylysine, serine, or threonine residues in proteins, which can be further elongated with sugar units.
What genes are involved in protein O-linked glycosylation via galactose?
Key genes include COLGALT1, COLGALT2, GLT25D1, GLT25D2, PLOD1, PLOD2, PLOD3, and B4GALT1, among others.
Where does protein O-linked glycosylation via galactose occur in the cell?
Hydroxylysine modification occurs in the endoplasmic reticulum and is predominantly found in collagen, while hydroxyproline modification occurs in the Golgi and is found only in plant proteins.
What is the role of galactosylation in IgA nephropathy?
Aberrant galactosylation of IgA1 leads to immune complex formation and kidney damage in IgA nephropathy, driven by pathways involving APRIL and IL-6 [2,3].
How is protein O-linked glycosylation via galactose studied?
It is studied using mass spectrometry, lectins, CRISPR screens, and computational modeling to characterize glycan structures and identify regulators [2,4].
Can CRISPR be used to study protein O-linked glycosylation via galactose?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable functional studies of genes involved in this pathway [1,4].
What diseases are associated with defects in protein O-linked glycosylation via galactose?
Diseases include IgA nephropathy, collagen-related connective tissue disorders, and infectious disease susceptibility [1,2,3,6,7].
How does galactosylation affect therapeutic antibodies?
Galactosylation of monoclonal antibodies is a critical quality attribute that affects effector functions and pharmacokinetics, and can be modulated in CHO cells [4,5].
What is the difference between hydroxylysine and hydroxyproline galactosylation?
Hydroxylysine galactosylation occurs in the endoplasmic reticulum and is found in collagen, while hydroxyproline galactosylation occurs in the Golgi and is plant-specific.
Why is protein O-linked glycosylation via galactose important for biotechnology?
It impacts the quality and efficacy of therapeutic glycoproteins, and its optimization is essential for biopharmaceutical production [4,5].
Conclusion
Protein O-linked glycosylation via galactose (GO:0180062) is a vital post-translational modification that influences protein function, extracellular matrix integrity, and immune regulation. Its dysregulation is implicated in IgA nephropathy, collagen disorders, and host-pathogen interactions, while its control is critical for biopharmaceutical production. Advances in CRISPR-based models and glycomics are accelerating our understanding of this pathway and its therapeutic potential [1,2,3,4,5,6,7].
References
- 1. Adeva-Andany MM et al.. 2016. Liver glucose metabolism in humans.. Biosci Rep 36(6) PMID: 27707936
- 2. Lai KN et al.. 2016. IgA nephropathy.. Nat Rev Dis Primers 2:16001 PMID: 27189177
- 3. Makita Y et al.. 2020. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.. Kidney Int 97(2):340-349 PMID: 31748116
- 4. Pranomphon R et al.. 2025. Modulation of Antibody Glycosylation in Chinese Hamster Ovary Cells: Experimental and Computational Analyses Provide Mechanistic Insights.. Biotechnol J 20(10):e70143 PMID: 41139990
- 5. Wang C et al.. 2018. Ultra-low carbon dioxide partial pressure improves the galactosylation of a monoclonal antibody produced in Chinese hamster ovary cells in a bioreactor.. Biotechnol Lett 40(8):1201-1208 PMID: 29923054
- 6. Wang W et al.. 2025. ILC3s regulate the gut microbiota via host intestinal galactosylation to limit pathogen infection in mice.. Nat Microbiol 10(3):654-666 PMID: 39962279
- 7. Itell HL et al.. 2024. Host cell glycosylation selects for infection with CCR5- versus CXCR4-tropic HIV-1.. Nat Microbiol 9(11):2985-2996 PMID: 39363105
